GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Dividends Received

Sensorion (XPAR:ALSEN) Dividends Received


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.


Sensorion Business Description

Traded in Other Exchanges
N/A
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.